PURPOSE: The aim of this study was to assess the accuracy and clinical impact of [(11)C]choline PET/CT for localizing occult relapse of prostate adenocarcinoma after radical prostatectomy. METHODS: Fourty-nine patients with prostate adenocarcinoma, radical prostatectomy, no evidence of metastatic disease, and occult relapse underwent [(11)C]choline PET/CT. Thirty-six of the patients had biochemical evidence and histological evaluation of local recurrence. Thirteen patients had PSA < 0.3 ng/ml and no evidence of active disease after 1 year follow-up. Focal nodular [(11)C]choline uptake in the prostatic fossa was visually assessed and graded on a five point scale. Maximum standardized radioactivity uptake value (SUV(max)) and the lesion size were measured. A receiver operating characteristic (ROC) analysis was performed and the clinical impact of the PET/CT study was determined. RESULTS: [(11)C]choline PET/CT was true positive in 23/33 patients and true negative in 12/13 controls. SUV(max) of local recurrence was 3.0 (median, range 0.6-7.4) and 1.1 (0.4-1.6) in controls (p = 0.0002). Lesion size was 1.7 cm (range 0.9-3.7). Area under the ROC curve for detecting relapse was 0.90 +/- 0.05 and 0.83 +/- 0.06 for visual evaluation and SUV(max), respectively. Sensitivity and specificity of [(11)C]choline PET/CT were 0.73 and 0.88, respectively. [(11)C]choline PET/CT identified 12/17 (71%) patients with a favourable biochemical response to local radiotherapy at 2 year (median, 0.8-3.2 range) follow-up. CONCLUSIONS: Focally increased [(11)C]choline uptake in the prostatic bed reliably predicted local low volume occult relapsing prostate adenocarcinoma after radical prostatectomy and identified 71% of patients with a favourable biochemical response to local radiotherapy.
PURPOSE: The aim of this study was to assess the accuracy and clinical impact of [(11)C]choline PET/CT for localizing occult relapse of prostate adenocarcinoma after radical prostatectomy. METHODS: Fourty-nine patients with prostate adenocarcinoma, radical prostatectomy, no evidence of metastatic disease, and occult relapse underwent [(11)C]choline PET/CT. Thirty-six of the patients had biochemical evidence and histological evaluation of local recurrence. Thirteen patients had PSA < 0.3 ng/ml and no evidence of active disease after 1 year follow-up. Focal nodular [(11)C]choline uptake in the prostatic fossa was visually assessed and graded on a five point scale. Maximum standardized radioactivity uptake value (SUV(max)) and the lesion size were measured. A receiver operating characteristic (ROC) analysis was performed and the clinical impact of the PET/CT study was determined. RESULTS: [(11)C]choline PET/CT was true positive in 23/33 patients and true negative in 12/13 controls. SUV(max) of local recurrence was 3.0 (median, range 0.6-7.4) and 1.1 (0.4-1.6) in controls (p = 0.0002). Lesion size was 1.7 cm (range 0.9-3.7). Area under the ROC curve for detecting relapse was 0.90 +/- 0.05 and 0.83 +/- 0.06 for visual evaluation and SUV(max), respectively. Sensitivity and specificity of [(11)C]choline PET/CT were 0.73 and 0.88, respectively. [(11)C]choline PET/CT identified 12/17 (71%) patients with a favourable biochemical response to local radiotherapy at 2 year (median, 0.8-3.2 range) follow-up. CONCLUSIONS: Focally increased [(11)C]choline uptake in the prostatic bed reliably predicted local low volume occult relapsing prostate adenocarcinoma after radical prostatectomy and identified 71% of patients with a favourable biochemical response to local radiotherapy.
Authors: Nobuyuki Oyama; Tom R Miller; Farrokh Dehdashti; Barry A Siegel; Keith C Fischer; Jeff M Michalski; Adam S Kibel; Gerald L Andriole; Joel Picus; Michael J Welch Journal: J Nucl Med Date: 2003-04 Impact factor: 10.057
Authors: Daniel T Schmid; Hubert John; Roland Zweifel; Tibor Cservenyak; Gerrit Westera; Gerhard W Goerres; Gustav K von Schulthess; Thomas F Hany Journal: Radiology Date: 2005-05 Impact factor: 11.105
Authors: Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun Journal: CA Cancer J Clin Date: 2003 Jan-Feb Impact factor: 508.702
Authors: Ludwig Rinnab; Joerg Simon; Richard E Hautmann; M V Cronauer; Kathrin Hohl; Andreas K Buck; Sven N Reske; Felix M Mottaghy Journal: World J Urol Date: 2009-02-21 Impact factor: 4.226
Authors: Michael Souvatzoglou; Matthias Eiber; Toshiki Takei; Sebastian Fürst; Tobias Maurer; Florian Gaertner; Hans Geinitz; Alexander Drzezga; Sibylle Ziegler; Stephan G Nekolla; Ernst J Rummeny; Markus Schwaiger; Ambros J Beer Journal: Eur J Nucl Med Mol Imaging Date: 2013-07-02 Impact factor: 9.236